Table 3.
Characteristics of patients with diabetes according to concomitant events
| 3. Diabetes w/o event | 4. Diabetes with event | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| NHIS | NHIS + Eze | HIS | HIS + Eze | p value* | NHIS | NHIS + Eze | HIS | HIS + Eze | p value* | |
| Nr. patients n (%) | 5661 (85) | 447 (7) | 532 (8) | 33 (1) | 2057 (54) | 325 (9) | 1289 (34) | 115 (3) | ||
| Adherent n (%) | 4777 (84) | 404 (90) | 461 (87) | 33 (100) | < 0.001 | 1677 (82) | 294 (91) | 1085 (84) | 106 (92) | < 0.001 |
| Total-chol (mg/dl)a | 154.2 (34) | 153.7 (37) | 149.8 (37) | 155.3 (48) | N.S | 138.8 (37) | 136.9 (34) | 130.5 (35) | 136.6 (44) | < 0.001 |
| LDL-chol (mg/dl)a | 81.7 (27) | 79.6 (30) | 79.2 (29) | 87.5 (39) | N.S | 73.1 (28) | 68.8 (27) | 67.6 (27) | 72.1 (36) | < 0.001 |
| HDL-chol (mg/dl)a | 49.5 (15) | 48.7 (14) | 46.4 (14) | 43 (9) | < 0.001 | 42.6 (14) | 43.7 (14) | 41.1 (13) | 41.5 (12) | < 0.01 |
| Triglycerides (mg/dl)a | 108.9 (70) | 122.5 (79) | 114.3 (74) | 109.2 (65) | < 0.001 | 100.7 (68) | 106.6 (71) | 97.6 (71) | 96 (61) | N.S |
| NON-HDL-chol (mg/dl)a | 104.7 (32) | 105 (35) | 103.4 (34) | 112.3 (48) | N.S | 96.2 (34) | 93.2 (31) | 89.4 (33) | 95.1 (43) | < 0.001 |
| GFR (ml/min/1.73 m2)a | 94.7 (33) | 92.5 (31) | 93.8 (32) | 98.7 (29) | N.S | 75.2 (37) | 71.8 (37) | 82 (36) | 86.5 (40) | < 0.001 |
| HbA1c (mmol/mol)a | 55.7 (13) | 56.4 (13) | 55.8 (13) | 56 (15) | N.S | 55.1 (14) | 54.4 (14) | 56.2 (15) | 56.9 (14) | N.S |
| CHD | 920 (45) | 175 (54) | 619 (48) | 72 (63) | < 0.001 | |||||
| Cerebrovascular disease | 790 (38) | 86 (27) | 531 (41) | 28 (24) | < 0.001 | |||||
| PAD | 8 (0) | N.I | N.I | 0 (0) | N.S | |||||
| ACEi/ARB | 3986 (70) | 320 (72) | 395 (74) | 26 (79) | N.S | 1502 (73) | 243 (75) | 1000 (78) | 91 (79) | < 0.05 |
| Beta blockers | 1588 (28) | 152 (34) | 213 (40) | 16 (49) | < 0.001 | 1116 (54) | 221 (68) | 816 (63) | 91 (79) | < 0.001 |
| CCB | 1669 (30) | 127 (28) | 147 (28) | 7 (21) | N.S | 742 (36) | 119 (37) | 491 (38) | 43 (37) | N.S |
| Fibrates | 64 (1) | 12 (3) | 14 (3) | 0 (0) | < 0.01 | 22 (1) | 5 (2) | 15 (1) | N.I | N.S |
| Insulin | 1366 (24) | 136 (30) | 154 (29) | 9 (27) | < 0.01 | 823 (40) | 144 (44) | 498 (39) | 49 (43) | N.S |
| Metformin | 3724 (66) | 258 (58) | 333 (63) | 25 (76) | < 0.01 | 906 (44) | 132 (41) | 643 (50) | 59 (51) | = 0.001 |
| Sulfonylureas | 1131 (20) | 88 (20) | 100 (19) | N.I | N.S | 290 (14) | 39 (12) | 174 (14) | 11 (10) | N.S |
| DPP-4 | 300 (5) | 36 (8) | 25 (5) | N.I | N.S | 171 (8) | 29 (9) | 89 (7) | 7 (6) | N.S |
| GLP-1 | 160 (3) | 17 (4) | 17 (3) | N.I | N.S | 29 (1) | 8 (3) | 26 (2) | 5 (4) | N.S |
| SLGT2 | 69 (1) | 12 (3) | 11 (2) | 0 (0) | < 0.05 | 24 (1) | 6 (2) | 17 (1) | 6 (5) | < 0.01 |
Opinion 05/2014 on “Anonymisation Techniques” drafted by the “European Commission Article 29 Working Party”, the analyses involving less than three patients were not reported, as potentially reconductable to single individuals. Therefore, results referred to ≤ 3 patients were reported as NI (not issuable)
CHD coronary heart disease, PAD peripheral artery disease, ACEi angiotensin converting-enzyme inhibitors, ARBs angiotensin II receptor blocker, CCB calcium channel blockers
*ANOVA P value for differences between groups (i.e., if < 0.05 not all group are equivalent)
aAnalyses performed on patients with at least one detection before index